Skip directly to page options Skip directly to A-Z link

Volume 30, Number 8—August 2024

Research

Fatal SARS-CoV-2 Infection among Children, Japan, January–September 20221

Shingo Mitsushima2, Yuichiro Yahata2, Yuuki TsuchihashiComments to Author , Chiaki Ikenoue, Munehisa Fukusumi, Shogo Otake, Tomoe Shimada, Takuya Yamagishi, Hajime Kamiya, Yusuke Kobayashi, Hitomi Kurosu, Mai Okuyama, Saeko Morino, Miho Shibamura, Sayaka Takanashi, Taro Kamigaki, Kanako Otani, Manami Nakashita, Hanae Ito, Ayako Miyazaki, Masaya Koshiko, Masanao Harakuni, Megumi Onuma, Hiroko Chiba, Maki Masutani, Natsu Sudani, Yuka Satsuki, Taketoshi Takara, Akira Oka, Tomohiro Katsuta, Naoki Shimizu, Akihiko Saitoh, Tetsuya Sakamoto, Motoi Suzuki, Tomimasa Sunagawa, and COVID-19 Fatal Pediatric Cases Database Group3
Author affiliations: National Institute of Infectious Diseases, Tokyo, Japan (S. Mitsushima, Y. Yahata, Y. Tsuchihashi, C. Ikenoue, M. Fukusumi, S. Otake, T. Shimada, T. Yamagishi, H. Kamiya, Y. Kobayashi, H. Kurosu, M. Okuyama, S. Morino, M. Shibamura, S. Takanashi, T. Kamigaki, K. Otani, M. Nakashita, H. Ito, A. Miyazaki, M. Koshiko, M. Harakuni, M. Onuma, H. Chiba, M. Masutani, N. Sudani, Y. Satsuki, T. Takara, M. Suzuki, T. Sunagawa); Saitama Children’s Medical Center, Saitama, Japan (A. Oka); St. Marianna University School of Medicine, Kanagawa, Japan (T. Katsuta, N. Shimizu); Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan (A. Saitoh); Teikyo University School of Medicine, Tokyo (T. Sakamoto)

Main Article

Table 3

Characteristics of 16 patients for whom central nervous system abnormalities were suspected of causing death in study of fatal SARS-CoV-2 infection among patients 0–19 years of age, Japan, January–September 2022*

Characteristics Value
Age group, y
0 0
1–4 5 (31)
5–11 9 (56)
12–19
 2 (13)
Sex
M 8 (50)
F
 8 (50)
Underlying disease
Yes 5 (31)
No
 11 (69)
Vaccination
None 11 (69)
Ineligible
 5 (31)
Symptoms/signs
Fever 14 (88)
Disturbance of consciousness 13 (81)
Seizure 11 (69)
Nausea/vomiting 8 (50)
Headache
 6 (38)
OHCA
Yes 3 (19)
No
 13 (81)
Days from symptom onset to first consultation
0–2 16 (100)
>3 0
Median (IQR)
 0.5 (0–1.0)
Days from symptom onset to cardiopulmonary arrest
0–4 11 (69)
5–9 0
>10 5 (31)
Median (IQR)
 2.0 (1.0–12.0)
Days from symptom onset to death
0–4 9 (56)
5–9 0
>10 7 (44)
Median (IQR) 3.5 (2.0–14.5)

*Values are no. (%) patients except as indicated. OHCA, out-of-hospital cardiac arrest, IQR, interquartile range.

Main Article

1Preliminary results from this study were presented in Japanese as a government surveillance report at https://www.niid.go.jp/niid/ja/2019-ncov/2559-cfeir/11727-20.html.

2These first authors contributed equally to this article.

3Members of the COVID-19 Fatal Pediatric Cases Database Group who contributed data are listed at the end of this article.

Page created: June 14, 2024
Page updated: July 20, 2024
Page reviewed: July 20, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external